Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPRA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPRA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPRA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPRA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPRA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000660524 | Oral cavity | EOLP | protein targeting | 68/2218 | 314/18723 | 4.95e-07 | 1.34e-05 | 68 |
GO:007097223 | Oral cavity | EOLP | protein localization to endoplasmic reticulum | 22/2218 | 74/18723 | 2.93e-05 | 4.23e-04 | 22 |
GO:007259921 | Oral cavity | EOLP | establishment of protein localization to endoplasmic reticulum | 15/2218 | 46/18723 | 1.71e-04 | 1.78e-03 | 15 |
GO:004504721 | Oral cavity | EOLP | protein targeting to ER | 12/2218 | 42/18723 | 2.71e-03 | 1.62e-02 | 12 |
GO:009015022 | Oral cavity | EOLP | establishment of protein localization to membrane | 45/2218 | 260/18723 | 5.73e-03 | 2.94e-02 | 45 |
GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
GO:00709728 | Prostate | BPH | protein localization to endoplasmic reticulum | 36/3107 | 74/18723 | 1.61e-10 | 9.22e-09 | 36 |
GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
GO:00725997 | Prostate | BPH | establishment of protein localization to endoplasmic reticulum | 23/3107 | 46/18723 | 1.71e-07 | 3.85e-06 | 23 |
GO:00450476 | Prostate | BPH | protein targeting to ER | 21/3107 | 42/18723 | 5.88e-07 | 1.15e-05 | 21 |
GO:00066134 | Prostate | BPH | cotranslational protein targeting to membrane | 15/3107 | 31/18723 | 4.00e-05 | 4.30e-04 | 15 |
GO:0006614 | Prostate | BPH | SRP-dependent cotranslational protein targeting to membrane | 10/3107 | 26/18723 | 6.33e-03 | 2.89e-02 | 10 |
GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
GO:000660519 | Prostate | Tumor | protein targeting | 109/3246 | 314/18723 | 6.11e-14 | 7.30e-12 | 109 |
GO:007097216 | Prostate | Tumor | protein localization to endoplasmic reticulum | 36/3246 | 74/18723 | 5.66e-10 | 2.95e-08 | 36 |
GO:007259913 | Prostate | Tumor | establishment of protein localization to endoplasmic reticulum | 23/3246 | 46/18723 | 3.87e-07 | 8.56e-06 | 23 |
GO:009015017 | Prostate | Tumor | establishment of protein localization to membrane | 77/3246 | 260/18723 | 6.46e-07 | 1.33e-05 | 77 |
GO:004504713 | Prostate | Tumor | protein targeting to ER | 21/3246 | 42/18723 | 1.24e-06 | 2.31e-05 | 21 |
GO:000661312 | Prostate | Tumor | cotranslational protein targeting to membrane | 15/3246 | 31/18723 | 6.78e-05 | 7.21e-04 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPRA | SNV | Missense_Mutation | | c.219C>G | p.Ile73Met | p.I73M | P08240 | protein_coding | deleterious(0.04) | possibly_damaging(0.606) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
SRPRA | SNV | Missense_Mutation | | c.175G>A | p.Asp59Asn | p.D59N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
SRPRA | SNV | Missense_Mutation | | c.787N>G | p.Thr263Ala | p.T263A | P08240 | protein_coding | tolerated(0.59) | benign(0) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SRPRA | SNV | Missense_Mutation | rs778409990 | c.1385N>C | p.Val462Ala | p.V462A | P08240 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | | c.1864N>A | p.Asp622Asn | p.D622N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | rs370707916 | c.1867N>G | p.Leu623Val | p.L623V | P08240 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |
SRPRA | SNV | Missense_Mutation | | c.583N>T | p.Pro195Ser | p.P195S | P08240 | protein_coding | tolerated(0.21) | benign(0) | TCGA-EW-A1P3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
SRPRA | insertion | Frame_Shift_Ins | novel | c.1419_1420insTCCCTTTACAACTTGA | p.Ala474SerfsTer23 | p.A474Sfs*23 | P08240 | protein_coding | | | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | insertion | Frame_Shift_Ins | novel | c.1829_1830insTGTCTTCAGTGTAGTACAAAGGCAGAGTGAGGGGGCTTGTGGCT | p.Ile611ValfsTer41 | p.I611Vfs*41 | P08240 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | rs558045090 | c.391N>T | p.Arg131Cys | p.R131C | P08240 | protein_coding | deleterious(0) | benign(0.052) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |